Despite global vaccination efforts, COVID-19 continues to pose significant risks, leading to severe complications and fatalities. These risks are driven by disrupted coagulation, impaired fibrinolysis, which is the process of breaking blood clots, and heightened inflammatory responses. The fibrinolytic system, crucial for maintaining balance within the coagulation cascade, relies on plasmin-mediated fibrin degradation.
Plasminogen activators convert plasminogen into plasmin, an enzyme that breaks down blood clots. Elevated levels of plasminogen activator inhibitor-1 (PAI-1) in COVID-19 patients disrupt this balance, leading to a hypofibrinolytic state with reduced plasmin generation, impaired clot dissolution, and a heightened risk of thrombosis. The situation is further complicated by polymorphisms in the PAI-1 gene, particularly the 4G/5G polymorphism in its promoter region, which has been linked to various cardiovascular conditions.
A recent study from Japan, published in Frontiers in Immunology on August 30, 2024, investigates how the 4G/5G polymorphism influences thrombotic and inflammatory responses in Japanese patients with COVID-19, shedding light on the genetic factors contributing to variations in COVID-19 outcomes. This research was conducted by Specially Appointed Associate Professor Beate Heissig and Associate Professor Koichi Hattori from Juntendo University Graduate School of Medicine, in collaboration with Dr. Tetiana Yatsenko from Juntendo University, and the.
